Astrazeneca Share News (AZN)

UPDATE 1-Pfizer to buy antibiotics business from AstraZeneca

* British firm sells non-core antibiotics unit to Pfizer * Says deal fits strategy of focusing on cancer and other areas * Pfizer will pay $550 mln on completion and $175 mln in 2019 * Will also pay sales-related payments and royalties (Adds details, shares) LONDON, Aug

AstraZeneca sells antibiotics business to Pfizer for £1.2bn

(ShareCast News) - AstraZeneca has agreed to sell its antibiotics business to US giant Pfizer for staged payments amounting to $1.6bn (£1.2bn) plus recurring, double-digit royalties on future sales. The FTSE 100 group said the sale would reinforces its focus on developing medicines in its three main

AstraZeneca to sell antibiotics business to Pfizer

LONDON, Aug 24 (Reuters) - Pharmaceutical company AstraZeneca said it had agreed to sell its small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5 billion. The portfolio includes approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which

FTSE 100 movers: Housebuilders lead equities higher

(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index. Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 J

AstraZeneca completes licensing agreement with LEO Pharma

(ShareCast News) - AstraZeneca has completed a licensing agreement with LEO Pharma, a specialist in dermatology care, for the global licence to monoclonal antibody tralokinumab in skin diseases. Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of $115m for the exclusive, gl

AstraZeneca wins UK cost approval for longer use of heart drug

LONDON, Aug 12 (Reuters) - Long term use of AstraZeneca's blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain's healthcare cost watchdog NICE said on Friday. Ticagrelor 60 mg -- sold in Britain as Brilique for just und

Thursday broker round-up

(ShareCast News) - Astrazeneca: Berenberg reiterates buy with a target price of 5600p. Legal & General: RBC maintains outperform with a 300p target. Lloyds: JP Morgan reiterates neutral with a 62p target. Centamin: RBC stays at speculative risk with a 190p target. Staffline: Berenberg reiterates

BROKER RATINGS SUMMARY: Barclays Cuts Travis Perkins To Underweight

Astrazeneca ups interest in Moderna Therapeutics with $140m investment

(ShareCast News) - Astrazeneca has upped its equity interest in Moderna Therapeutics with a $140m investment as part of the biotechnology company's preferred-stock financing. Astrazeneca had already purchased a stake in Massachusetts-based Moderna to develop messenger RNA medicines for the potential

AstraZeneca bets another $140 mln on Moderna's "messenger" drugs

LONDON, Aug 10 (Reuters) - AstraZeneca has invested another $140 million in Moderna Therapeutics, the U.S. biotech "unicorn" which already has a cash pile of around $1 billion and is developing drugs based on a molecule known as messenger RNA. The British drugmaker said on Wednesday that t

AstraZeneca Invests USD140 Million In US's Moderna Therapeutics

Tuesday broker round-up

(ShareCast News) - Aviva: Goldman Sachs reiterates buy with a target price of 480p. Antofagasta: RBC maintains sector perform with a 500p target. Informa: Numis reiterates buy with a 845p target. Astrazeneca: JP Morgan stays at neutral with a 4900p target. Topps Tiles: Berenberg reiterates hold w

BROKER RATINGS SUMMARY: Cantor Upgrades easyJet To Buy From Hold

AstraZeneca drug fails in lung cancer trial

(ShareCast News) - Pharmaceutical giant AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib on Tuesday, in combination with docetaxel chemotherapy, as second-line treatment in patients with KRAS mutation-positive locally-advanced or metastatic non-sm

AstraZeneca drug selumetinib fails in lung cancer study

LONDON, Aug 9 (Reuters) - AstraZeneca's cancer drug pipeline suffered a setback on Tuesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer. Hopes for the medicine had already been reduced after it failed in another study for treating a ra